Abbasi Muhammad Athar, Rubab Kaniz, Siddiqui Sabahat Zahra, Hassan Mubashir, Raza Hussain, Shah Syed Adnan Ali, Shahid Muhammad, Kloczkowski Andrzej
Department of Chemistry, Government College University, Lahore 54000, Pakistan.
The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children Hospital, Columbus, Ohio 43205, United States.
ACS Omega. 2023 Jun 14;8(25):22899-22911. doi: 10.1021/acsomega.3c01882. eCollection 2023 Jun 27.
The aim of this work was to bring forth some new hybrid molecules having pharmacologically potent indole and 1,3,4-oxadiazole heterocyclic moieties unified with a propanamide entity. The synthetic methodology was initiated by esterification of 2-(1-indol-3-yl)acetic acid () in a catalytic amount of sulfuric acid and ethanol in excess, to form ethyl 2-(1-indol-3-yl)acetate (), which was converted to 2-(1-indol-3-yl)acetohydrazide () and further transformed to 5-(1-indole-3-yl-methyl)-1,3,4-oxadiazole-2-thiol (). 3-Bromopropanoyl chloride () was reacted with various amines (-) in aqueous alkaline medium to generate a series of electrophiles, 3-bromo--(substituted)propanamides (-), and these were further reacted with nucleophile in DMF and NaH base to yield the targeted -(substituted)-3-{(5-(1-indol-3-ylmethyl)-1,3,4-oxadiazol-2-yl)sulfanyl}propanamides (-). The chemical structures of these biheterocyclic propanamides were confirmed by IR, H NMR, C NMR, and EI-MS spectral techniques. These compounds were evaluated for their enzyme inhibitory potentials against the α-glucosidase enzyme, where the compound showed promising enzyme inhibitory potential with an IC value less than that of the standard acarbose. Molecular docking results of these molecules were coherent with the results of their enzyme inhibitory potentials. Cytotoxicity was assessed by the percentage of hemolytic activity method, and these compounds generally exhibited very low values as compared to the reference standard, Triton-X. Hence, some of these biheterocyclic propanamides might be considered as salient therapeutic agents in further stages of antidiabetic drug development.
这项工作的目的是合成一些新的杂化分子,这些分子具有药理学活性的吲哚和1,3,4 - 恶二唑杂环部分,并与丙酰胺实体结合。合成方法首先是在催化量的硫酸和过量乙醇存在下,将2 - (1 - 吲哚 - 3 - 基)乙酸()进行酯化反应,生成2 - (1 - 吲哚 - 3 - 基)乙酸乙酯(),然后将其转化为2 - (1 - 吲哚 - 3 - 基)乙酰肼(),并进一步转化为5 - (1 - 吲哚 - 3 - 基 - 甲基)-1,3,4 - 恶二唑 - 2 - 硫醇()。3 - 溴丙酰氯()在碱性水溶液中与各种胺(-)反应,生成一系列亲电试剂,即3 - 溴 - (取代)丙酰胺(-),然后这些亲电试剂在N,N - 二甲基甲酰胺(DMF)和氢化钠(NaH)碱存在下与亲核试剂反应,生成目标产物 - (取代)-3 - {(5 - (1 - 吲哚 - 3 - 基甲基)-1,3,4 - 恶二唑 - 2 - 基)硫烷基}丙酰胺(-)。这些双杂环丙酰胺的化学结构通过红外光谱(IR)、氢核磁共振谱(¹H NMR)、碳核磁共振谱(¹³C NMR)和电子轰击质谱(EI - MS)光谱技术得到证实。对这些化合物进行了α - 葡萄糖苷酶抑制潜力的评估,其中化合物显示出有前景的酶抑制潜力,其半数抑制浓度(IC)值低于标准药物阿卡波糖。这些分子的分子对接结果与其酶抑制潜力的结果一致。通过溶血活性百分比法评估细胞毒性,与参考标准曲拉通 - X(Triton - X)相比,这些化合物通常表现出非常低的值。因此,在抗糖尿病药物开发的进一步阶段,这些双杂环丙酰胺中的一些可能被视为重要的治疗药物。